THE SITUATION AND SOME RELATED FACTORS OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN HYPERTENSION AT INTERVENTION CARDIOLOGY – NEUROLOGY DEPARTMENT OF CAN THO UNIVERSITY OF MEDICINE AND PHARMACY HOSPITAL IN 2023
Main Article Content
Abstract
Background: Hypertension is a common disease in the world. Heart failure is one of the final consequences of cardiovascular disease in general and hypertension in particular, which is currently a significant burden for the health sector worldwide. Objectives: The prevalence and some related factors of heart failure with preserved ejection fraction in hypertension at Intervention Cardiology – Neurology Department of Can Tho University of Medicine and Pharmacy Hospital in 2023. Materials and methods: A cross-sectional study was conducted on 100 primary hypertension patients 18 years old or older. The data is processed by SPSS 22.0 software. Results: The rate of heart failure with preserved ejection fraction in patients with hypertension accounted for 47%. Gender and BMI were not statistically related factors, with p of 0.16 and 0.93. Age, duration of hypertension, the highest systolic blood pressure, HbA1C, LDL-c, and sedentary lifestyle were the related factors that increase the risk of heart failure with preserved ejection fraction (p<0.05). Conclusion: Heart failure with preserved ejection fraction accounted for a relatively high rate in patients with primary hypertension. Age, duration of hypertension, the highest systolic blood pressure, HbA1C, LDL-c, and sedentary lifestyle were the related factors that increase the risk of heart failure with preserved ejection fraction.
Article Details
Keywords
Primary hypertension, heart failure with preserved ejection fraction, related factors
References
2. Kanako Teramoto, Tiew-Hwa Katherine Teng, Chanchal Chandramouli. Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction. Cardilac Failure Review. 2022. 8, 27, DOI:https://doi.org/10.15420/cfr.2022.06.
3. Hội Tim Mạch học Việt Nam. Khuyến cáo về chẩn đoán và điều trị tăng huyết áp. 2022. 4-8.
4. Theresa A McDonagh, Marco Metra, Marianna Admo. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021. 42(36), 3599-3726, DOI: https://doi.org/10.1093/eurheartj/ehab368.
5. Nguyễn Thị Diễm, Nguyễn Anh Vũ, Đỗ Doãn Lợi. Đánh giá chức năng tâm trương thất trái bằng siêu âm đánh dấu mô cơ tim ở bệnh nhân tăng huyết áp. Trường Đại học Y Dược Huế. 2019.
6. Mark P. Silverman, Trevor C. Lipscombe. Exact Statistical Distribution of the Body Mass Index: Analysis and Experimental Confirmation. Open Journal of Statistics. 2022. 12(3), 324-356. DOI: https://doi.org/10.4236/ojs.2022.123022.
7. Lê Minh Hữu, Nguyễn Trung Kiên, Phạm Thị Tâm. Nguyên cứu tình hình vi đạm niệu ở bệnh nhân tăng huyết áp và một số yếu tố liên quan tại tỉnh Vĩnh Long. Tạp chí Y Dược học Cần Thơ. 2019. 19, 11-12.
8. Nguyễn Hoàng Mây. Nghiên cứu tình hình, đặc điểm và đánh giá kết quả điều trị suy tim phân suất tống máu bảo tồn ở bệnh nhân tăng huyết áp nguyên phát tại khoa Nội tim mạch Bệnh viện Đa khoa Thành phố Cần Thơ. Trường Đại học Y Dược Cần Thơ. 2021. 45-50.
9. Trần Đỗ Thanh Phong, Nguyễn Trung Kiên. Nguyên cứu tình hình kiểm soát huyết áp và đánh giá kết quả can thiệp ở bệnh nhân tăng huyết áp nguyên phát tại huyện Châu Thành A, tỉnh Hậu Giang. Tạp chí Y Dược học Cần Thơ, 2019, 11-12.
10. Guang Hao, Xin Wang, Zuo Chen, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey 2012–2015. European Journal of Heart Failure. 2019. 21, 1329-1337, DOI: 10.1002/ejhf.1629.
11. Rolf Wachter, Sanjiv J Shah, Martin R Cowie, et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure. 2020. 7, 856-864. DOI: 10.1002/ehf2.12694.
12. Scott D Solomon, John IV McMurray. Angiotensin – Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019. 381, 1609-1620. DOI: 10.1002/ehf2.12694.
13. Stefan D Anker, Javed Butler, Gerasimos Filippatos, et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. European Journal of Heart Failure. 2020. 22(12), 2383-2392. DOI: 10.1002/ejhf.2064.